Researchers reported a point‑of‑care test for AAV8 binding antibodies using Chembio’s Dual Path Platform (DPP), enabling rapid detection of anti‑AAV8 antibodies in plasma, serum and whole blood. The assay aims to address a common exclusion criterion for AAV‑based gene therapies—preexisting humoral immunity—and to streamline patient screening at the clinic. Separately, teams publishing in Gene Therapy identified novel AAV capsid variants with markedly improved transduction of human vascular endothelial cells, offering vector options that could bypass current tropism and neutralization limits. Together, the diagnostic and vector advances target two core constraints in systemic AAV gene delivery: immune preclusion and inadequate endothelial transduction.